Clinical trials: Tislelizumab
Potentially Resectable Locally Advanced Intrahepatic Cholangiocarcinoma and Gallbladder Cancer
Tislelizumab Combined With Lenvatinib and GEMOX Versus Tislelizumab Combined With GEMOX in Conversion Therapy of ICC and GBC.
This is an Open Phase II Clinical Study of Tislelizumab Combined with Lenvatinib and GEMOX Versus Tislelizumab Combined with GEMOX in the Treatment of Locally Advanced Intrahepatic Cholangiocarcinoma and Gallbladder Cancer.
- Trial name
- NCT05620498
- Testing
- tislelizumab+lenvatinib+GMOX, tislelizumab+GEMOX
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Lung Cancer (Locally Advanced or Metastatic)
The Efficacy of Tislelizumab Combined With Albumin-bound Paclitaxel and Platinum-based Chemotherapy in Patients With KRAS-mutated Lung Cancer
To determine the optimal objective response rate (ORR) of tislelizumab combined with albumin-bound paclitaxel and platinum agents in patients with KRAS-mutant lung cancer who are ineligible for curative surgery
- Trial name
- NCT07638878
- Testing
- tislelizumab in combination with nab-paclitaxel and platinum chemotherapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Guangzhou Medical University
Gastric Cancer
A Benefit Population Atlas of nICT Versus nCT for LAGC
The purpose of this observational study is to evaluate the impact of different neoadjuvant therapies on patients with locally advanced gastric cancer.
- Trial name
- NCT07098104
- Testing
- Immunotherapy
- Where
- China
- Volunteers
- 291 people
- Sponsor
- Cheng Chen
Locally Advanced Rectal Cancer
Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer
To explore the complete response (CR) rate of modified short-course radiotherapy plus CAPOX and Tislelizumab versus Long-course Chemoradiotherapy plus Tislelizumab for locally advanced rectal cancer.
- Trial name
- NCT07469306
- Testing
- Modified Short-course radiotherapy, Long-course radiotherapy, Oxaliplatin
- Where
- 3 sites in China
- Volunteers
- 130 people
- Sponsor
- Fujian Cancer Hospital
Esophagus Cancer
Tislelizumab Combined With Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma Followed by CRT or Surgery
To explore the non-inferiority of the 2y-OS rate of tislelizumab combined with chemotherapy after sequential CRT in the treatment of resectable esophageal squamous cell carcinoma compared with the surgical group
- Trial name
- NCT07046221
- Testing
- Tislelizumab, Albumin-Bound Paclitaxel, cis-platinum
- Volunteers
- 60 people
- Sponsor
- Fujian Cancer Hospital
Gastric Cancer Stage
Perioperative Tislelizumab Plus Chemotherapy Versus Chemotherapy Alone in MHC-II-Positive Gastric/GEJ Cancer
Investigators has conducted a series of studies on patient selection for perioperative immunotherapy in locally advanced gastric cancer.
- Trial name
- NCT07068516
- Testing
- Tislelizumab, SOX or CAPOX regimen
- Where
- China
- Volunteers
- 470 people
- Sponsor
- Xiangdong Cheng
Head and Neck Squamous Cell Carcinoma
Intra-arterial Chemotherapy Combined with Radiotherapy and Immunotherapy for HNSCC
This study pioneers a novel approach by integrating a new auxiliary chemo-immunotherapy regimen, which is then followed by an evaluation of the potential for surgical resection.
- Trial name
- NCT06725498
- Testing
- Tislelizumab-jsgr, Cisplatin, Albumin-Bound Paclitaxel
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Beijing Tongren Hospital
Gastroesophageal Adenocarcinoma
Paclitaxel, Ramucirumab and Tislelizumab Switch Maintenance in Advanced HER2-negative and PD-L1 TAP Score of 5 or More Advanced Gastroesophageal Adenocarcinoma
ARMANI-2/ENGIC8 is a randomized, open-label, phase III trial evaluating a switch maintenance strategy in patients with previously untreated, locally advanced unresectable or metastatic, HER2-negative and PD-L1-positive…
- Trial name
- ARMANI-2 (NCT07763171)
- Testing
- FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin), CAPOX (oxaliplatin/capecitabine), CDDP, 5 Fu
- Where
- 42 sites in Germany, Italy and 1 more
- Volunteers
- 244 people
- Sponsor
- Gruppo Oncologico del Nord-Ovest
Cervical Cancer
AdvanTIG-202: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Previously Treated Recurrent or Metastatic Cervical Cancer
This study tested how well and how safely the drug tislelizumab, given either alone or with another drug called ociperlimab (BGB-A1217), worked in people with cervical cancer that had come back or spread after previous…
- Trial name
- NCT04693234
- Testing
- Tislelizumab, Ociperlimab
- Where
- 68 sites in Bulgaria, China and 6 more
- Volunteers
- 178 people
- Sponsor
- BeiGene
Gastric Cancer
SOX Combined With Tislelizumab and LDRT for Neoadjuvant Treatment of Locally Advanced Gastric Cancer
Neoadjuvant chemotherapy or chemoradiotherapy has become the standard neoadjuvant regimen for locally advanced G/GEJ cancer and has been recommended by a series of treatment guidelines.
- Trial name
- NCT06266871
- Testing
- SOX+Tislelizumab+LDRT
- Volunteers
- 64 people
- Sponsor
- West China Hospital
Hepatocellular Carcinoma
Comparing the Combination of Trastuzumab and Regorafenib With Regorafenib Monotherapy for Advanced Hepatocellular Carcinoma After First-line Treatment
At present, there is no standard treatment plan for hepatocellular carcinoma after the progress of first-line target immunotherapy.
- Trial name
- NCT07078305
- Testing
- Regorafenib and tislelizumab, Regorafenib
- Volunteers
- 134 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Gastric Junction Adenocarcinoma, Gastric Cancer
Safety and Efficacy Study of Sorbitol With Neoadjuvant Chemotherapy Combined With Tirellizumab (PD-1 Inhibitor) in Patients With Locally Advanced Gastric Cancer
The goal of this clinical trial is to learn if sorbitol works to enhance the therapeutic effect of neoadjuvant chemotherapy combined with Tirellizumab (PD-1 inhibitor) in patients with locally advanced gastric cancer.
- Conditions
- Gastric Junction Adenocarcinoma, Gastric Cancer, Immunotherapy, Neoadjuvant Therapies
- Trial name
- SNCCTGC (NCT06826079)
- Testing
- Sorbitol + PD-1 inhibitor + SOX chemotherapy, PD-1 inhibitor + SOX chemotherapy
- Where
- China
- Volunteers
- 86 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
ESCC, Tislelizumab
Prospective, Open-label, Multi-cohort Study of Becotatug Vedotin With Tislelizumab and Chemotherapy in Esophageal Squamous Cell Carcinoma - Phase 2
Esophageal squamous cell carcinoma (ESCC) is a common malignant tumor worldwide, with particularly high incidence in East Asian regions such as China, and is associated with poor patient prognosis.
- Conditions
- ESCC, Tislelizumab, Chemotherapy, Becotatug Vedotin
- Trial name
- NCT07531979
- Testing
- Tislelizumab, Becotatug Vedotin, Cisplatin
- Where
- China
- Volunteers
- 93 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Locally Advanced Prostate Cancer, Oligometastatic Prostate Cancer
Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO)
To evaluated the safety and efficacy of genomic biomarker-guided neoadjuvant therapy for locally advanced and oligometastatic prostate cancer.
- Trial name
- SEGNO (NCT06387056)
- Testing
- Rezvilutamide, Goserelin Microspheres for Injection, Docetaxel
- Where
- China
- Volunteers
- 40 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Esophagus Cancer
Tislelizumab Combined With Chemotherapy for the Perioperative Treatment of Esophageal Squamous Carcinoma
Evaluating the rate of pathologic complete remission in patients with squamous esophageal cancer treated perioperatively with tislelizumab in combination with chemotherapy
- Trial name
- NCT07019181
- Testing
- Tislelizumab, albumin-bound paclitaxel, Nedaplatin
- Volunteers
- 26 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Gastric Cancer
Safety and Efficacy of NK510 to Treat Gastric Cancer
This study will evaluate the safety and efficacy of NK510 in the treatment of relapsed and refractory advanced gastric cancer.NK510 will be administered in combination with PD-1 blockade or monoclonal anti-HER2 antibody.
- Trial name
- NCT06098898
- Testing
- NK510, Tislelizumab，atezolizumab or Trastuzumab
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Base Therapeutics (Shanghai) Co., Ltd.
Advanced Squamous Non-Small-Cell Lung Cancer
Trilaciclib Prior to Chemotherapy Plus Tislelizumab as 1L Treatment for Advanced Squamous Non-Small-Cell Lung Cancer
The purpose of this study is to explore the myeloprotective effects of trilaciclib in advanced squamous non-small cell lung cancer patients receiving a combination therapy of chemotherapy(carboplatin+paclitaxel) and immune…
- Trial name
- NCT05900921
- Testing
- Trilaciclib, Carboplatin, Paclitaxel
- Volunteers
- 132 people
- Sponsor
- Sichuan University
Esophageal Squamous Cell Carcinoma
Short-course Hypofractionated Radiotherapy in Combination With Raltitrexed and Tislelizumab
The goal of this observational study was to explore the safety and efficacy of short course hypofractionated radiotherapy combined with Raltitrexed and Tislelizumab in the treatment of patients with relapsed or advanced…
- Trial name
- SCHRT (NCT06408584)
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Anhui Provincial Hospital
Esophageal Squamous Cell Carcinoma, Locally Advanced Esophageal Squamous Cell Carcinoma
Combination of Tislelizumab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-002)
Definitive chemoradiotherapy (CRT) is the standard treatment option for unresectable locally advanced esophageal cancer (EC). However, as high as more than 40% of EC patients experienced locoregional recurrence after concurrent…
- Trial name
- EC-CRT-002 (NCT05520619)
- Testing
- Paclitaxel, Cisplatin, tislelizumab, Radiotherapy
- Where
- China
- Volunteers
- 114 people
- Sponsor
- Sun Yat-sen University
Non-Small Cell Lung Cancer
SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC
The aim of this clinical trial is to understand whether spatial fractionated radiotherapy (SFRT) in combination with tislelizumab and platinum-based doublet chemotherapy given concurrently as induction treatment is effective in…
- Trial name
- NCT07131319
- Testing
- Spatially Fractionated Radiotherapy (SFRT), Tislelizumab, Carboplatin, Pemetrexed, Tislelizumab, paclitaxel, Carboplatin
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Second Affiliated Hospital of Nanchang University